Skip to main content
Hit enter to search or ESC to close
Search
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Press Releases
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Press Releases
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
June 29, 2026
Enveric Biosciences Announces Participation in 2026 BIO International Convention
June 16, 2026
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
June 9, 2026
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
June 2, 2026
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
May 19, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
May 15, 2026
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
May 13, 2026
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
May 5, 2026
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
April 21, 2026
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 17, 2026
1
2
3
…
20
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin